421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors
| Autor: | Anna Olsson-Brown, Joseph Sacco, Mark Middleton, Kevin Harrington, Robert Coffin, Howard Kaufman, Suzanne Thomas, Praveen Bommareddy, Francesca Aroldi, Pablo Nanclares, Lavita Menezes, Selda Samakoglu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020) |
| Druh dokumentu: | article |
| ISSN: | 2051-1426 |
| DOI: | 10.1136/jitc-2020-SITC2020.0421 |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|